RecruitingPhase 4NCT06336317

Effect of infLuenza vaccInation After Myocardial INfArction on Cardiac inflammaTory responsE

Effect of infLuenza vaccInation After Myocardial INfArction on Cardiac inflammaTory responsE - a Randomized, Double-blind, Placebo-controlled, Trial (ELIMINATE Trial)


Sponsor

Region Örebro County

Enrollment

90 participants

Start Date

Apr 24, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this randomized, double-blind, placebo-controlled clinical trial is to investigate the immunological effects of influenza vaccination outside of the influenza season on arterial inflammation in patients with a recent acute myocardial infarction (AMI). The primary objective is to compare the effects of influenza vaccination to those of a placebo in reducing post-myocardial infarction coronary inflammation as measured by coronary computed tomography angiography (CCTA). The main questions it aims to answer are: Does influenza vaccination reduce arterial inflammation as measured by CCTA at week 8 after percutaneous coronary intervention (PCI) in comparison to baseline? Does influenza vaccination modulate systemic inflammation as measured by blood biomarkers and in-vitro challenge tests at week 8 after PCI in comparison to baseline? Researchers will compare the effects of influenza vaccination with those of a placebo.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Influenza vaccine and a biological treatment called Placebo for people with acute myocardial infarction, cardiovascular diseases, and other related conditions. The study is currently recruiting participants at 3 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALInfluenza vaccine

Inactivated, split virus or surface antigen Suspension for injection, prefilled syringe ATC code: J07BB02

BIOLOGICALPlacebo

Sodium Chloride Solution for infusion, 9mg/ml ATC code: B05BB01


Locations(3)

Aarhus University Hospital, Department of Cardiology

Aarhus, Denmark

Örebro University Hospital

Örebro, Sweden

Cambridge University Hospitals NHS Foundation Trust

Cambridge, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06336317


Related Trials